Enhanced PTH Compounds and Systems for Hypoparathyroidism Treatment

The present invention relates to novel PTH compounds, delivery systems, and methods that improve the treatment of hypoparathyroidism by achieving a peak-to-trough ratio of less than 4 within one administration interval, providing a more efficient, safer, and patient-friendly treatment option.

The original patent disclosed PTH compounds with low peak-to-trough ratios, but it had limitations in terms of administration frequency, delivery methods, and pharmacokinetic profile control. The present inventive concept addresses these limitations by introducing novel PTH compounds, wearable patches, conjugation with polyethylene glycol, stabilizers, and machine learning algorithms to optimize administration, thereby providing a more efficient and safer treatment option for hypoparathyroidism patients.

The inventive concept comprises four main aspects: (1) a system for treating hypoparathyroidism using a wearable patch that administers PTH compounds subcutaneously at a rate achieving a peak-to-trough ratio of less than 4 within one administration interval; (2) a method for enhancing the pharmacokinetic profile of a PTH compound by conjugating it with a polyethylene glycol (PEG) moiety with a molecular weight of at least 20 kDa; (3) a pharmaceutical composition comprising a PTH compound and a sugar molecule stabilizer that exhibits a peak-to-trough ratio of less than 4 within one administration interval; and (4) a device and method for optimizing the administration of a PTH compound using a machine learning algorithm to predict the pharmacokinetic profile and adjust the administration rate accordingly. These aspects work together to provide a more efficient, safer, and patient-friendly treatment option for hypoparathyroidism.

The inventive concept's novelty lies in the combination of these four aspects, which provide a more efficient and safer treatment option for hypoparathyroidism patients. The inventive step is in the introduction of wearable patches, PEG conjugation, sugar molecule stabilizers, and machine learning algorithms, which overcome the limitations of the original patent and provide a more patient-friendly treatment option.

Alternative embodiments of the inventive concept may include using different types of wearable patches, varying the molecular weight of the PEG moiety, using different sugar molecule stabilizers, or employing different machine learning algorithms. These variations can help ensure broad conceptual coverage and adaptability to different patient needs and treatment scenarios.

The inventive concept has significant commercial potential in the treatment of hypoparathyroidism, offering a more efficient, safer, and patient-friendly treatment option. The target market includes pharmaceutical companies, medical device manufacturers, and healthcare providers specializing in endocrinology and hormone replacement therapy.